ArticleBMC pregnancy and childbirth2026
Association between timing of antenatal corticosteroid and developmental outcomes in children born late preterm by high-risk pregnancies.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveHigh-risk pregnancies often receive antenatal corticosteroids (ACS) before 34 weeks, even when delivery occurs in the late preterm period. We aimed to evaluate whether the timing of ACS exposure is associated with developmental delay in late preterm infants born to high-risk mothers.
methodsWe conducted a national, retrospective cohort study of 40,119 singleton late preterm (LPI) live births born in Taiwan between January 1, 2004, and December 31, 2011, followed up until December 31, 2018. We defined high-risk pregnancies based on four clinical conditions: diabetes mellitus, advanced maternal age, hypertensive complications, and cesarean delivery, identified from claims data. The primary outcome is developmental delay (DD).
resultsAmong 40,119 LPI, 4,730 (11.8%) had exposure to ACS, with the majority (68.4%) exposed to ACS before 34 weeks. Compared to LPT without ACS exposure, those exposed to ACS at 34–36 weeks showed no increased risk of DD (aHR: 0.93[95% CI, 0.80–1.09]), whereas those with ACS before 34 weeks had significantly elevated risk of DD (aHR: 1.12 [95% CI, 1.01–1.24]), especially in infants born to diabetic or older age mothers (aHR: 1.43 [95% CI, 1.13–1.80]; 1.48 [95% CI, 1.11–1.97]).
conclusionExposure to ACS at 34–36 weeks was not associated with an increased risk of DD in any high-risk pregnancy subgroup. In contrast, ACS exposure before 34 weeks, particularly among infants born to mothers with diabetes or of advanced maternal age, was associated with a modestly elevated risk. These findings suggest potential susceptibility in specific high-risk groups not previously recognized, underscoring the need for further research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.